Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Core Insights - Taysha Gene Therapies, Inc. will report its financial results for the full year ended December 31, 2024, on February 26, 2025, at 8:30 AM Eastern Time [1] - The company focuses on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system [2] Company Overview - Taysha Gene Therapies is a clinical-stage biotechnology company dedicated to developing gene therapies for severe monogenic diseases, particularly targeting Rett syndrome [2] - The lead clinical program, TSHA-102, is aimed at treating Rett syndrome, which currently lacks approved disease-modifying therapies [2] - The management team possesses proven experience in gene therapy development and commercialization, leveraging a clinically and commercially validated AAV9 capsid [2]